Valeant Pharmaceuticals International Inc (VRX)

31.27
0.73 2.40
NYSE : Health Care
Prev Close 30.54
Open 31.09
Day Low/High 30.97 / 31.50
52 Wk Low/High 18.55 / 245.82
Volume 2.32M
Avg Volume 29.81M
Exchange NYSE
Shares Outstanding 347.54M
Market Cap 10.84B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.

Crude Oil, Health Care Team Up to Pull Wall Street Lower

Crude Oil, Health Care Team Up to Pull Wall Street Lower

A selloff in crude oil and health care stocks led Wall Street into the red on Wednesday.

Stressed Out: Valeant, LendingClub and Retailers Join Our Distress List as Steelmakers Fall Off

Stressed Out: Valeant, LendingClub and Retailers Join Our Distress List as Steelmakers Fall Off

The market has cured many stressed out players, but also created new ones.

Stocks Waver as Investors Wait for Fed Clarity

Stocks Waver as Investors Wait for Fed Clarity

Wall Street will get more clues on the Fed's rate hike plans later this week, but uncertainty over what they might be led to jittery trading on Monday.

Valeant's C-Suite Sees Another Shake-Up

Valeant's C-Suite Sees Another Shake-Up

Paul Herendeen, former CFO of Zoetis, will assume those duties as his new employer eyes divestitures.

Stocks Struggle for Direction as Jackson Hole Conference Looms

Stocks Struggle for Direction as Jackson Hole Conference Looms

Stocks fluctuate Monday afternoon as a selloff in crude oil hits the energy sector and Federal Reserve speeches at the end of the week leave investors wary.

Valeant Shares Rise on New CFO Appointment

Valeant Shares Rise on New CFO Appointment

Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.

Jim Cramer: New Valeant CFO is 'Solid'

Jim Cramer: New Valeant CFO is 'Solid'

Valeant's new CFO Paul Herendeen is a 'solid' performer and a welcome addition to the beleaguered company, says Jim Cramer

Jim Cramer -- Valeant Investors Should Welcome a High-Quality CFO

Jim Cramer -- Valeant Investors Should Welcome a High-Quality CFO

Cramer said investors should be cheering the reported arrival of CFO Paul Herendeen at Valeant.

U.S. Stocks Fall as Oil Prices Slump; Federal Reserve in Focus This Week

U.S. Stocks Fall as Oil Prices Slump; Federal Reserve in Focus This Week

U.S. stocks moved lower Monday as oil prices dipped back below $50 a barrel.

Stressed Out: Valeant, LendingClub and Retailers Join the List as Steelmakers Break the Mold

Stressed Out: Valeant, LendingClub and Retailers Join the List as Steelmakers Break the Mold

The market has cured many stressed out players, but also created new ones.

Morning Movers: PFE, VRX, VIAB, FL, UA

Morning Movers: PFE, VRX, VIAB, FL, UA

Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.

Valeant (VRX) Stock Climbs, Hires Zoetis' Herendeen as CFO

Valeant (VRX) Stock Climbs, Hires Zoetis' Herendeen as CFO

Valeant (VRX) appointed Paul Herendeen, an executive at animal healthcare company Zoetis (ZTS), as its new CFO on Monday.

Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy

Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy

A potential blockbuster drug deal is reportedly in the works.

HAIN, AMZN, WFM: Jim Cramer's Views

HAIN, AMZN, WFM: Jim Cramer's Views

Cramer shares his views on how to handle Hain-type problems. Valeant, Amazon and Whole Foods are among the stocks discussed.

Valeant (VRX) Stock Falls on T. Rowe Price Lawsuit

Valeant (VRX) Stock Falls on T. Rowe Price Lawsuit

Valeant (VRX) stock was trading lower this afternoon as T. Rowe Price alleges that it lost billions of dollars due to the company's 'fraudulent scheme.'

Wells Fargo Analyst Maris Weighs In on Valeant (VRX) Lawsuit on CNBC

Wells Fargo Analyst Maris Weighs In on Valeant (VRX) Lawsuit on CNBC

Valeant Pharmaceuticals (VRX) is being sued by T. Rowe Price, as the mutual fund is seeking billions over allegations Valeant was running a fraudulent operation.

Stocks Struggle for Gains as Crude Oil Rallies for Sixth Session

Stocks Struggle for Gains as Crude Oil Rallies for Sixth Session

Stocks post slight gains on Thursday as another rally in crude oil overshadows lingering concerns over the Federal Reserve 's divided opinions on interest rates.

Take the Pain and Exit Hain

Take the Pain and Exit Hain

Why you shouldn't bottom-fish the troubled organic-food maker.

Stock Futures Slip as Walmart Gains, Cisco Falls

Stock Futures Slip as Walmart Gains, Cisco Falls

Stock futures are little changed Thursday as investors digest earnings from the likes of Walmart and Cisco.

Valeant (VRX) Stock Higher on Credit Facility Amendment

Valeant (VRX) Stock Higher on Credit Facility Amendment

Valeant (VRX) stock was advancing in pre-market trading after lenders approved a credit facility amendment.

Choppy Session Ends Higher After Minutes Show Divided Fed

Choppy Session Ends Higher After Minutes Show Divided Fed

Wall Street was short-changed any clarity over a rate-hike timeline on Wednesday after the release of minutes from the July meeting showed a split Federal Reserve.

Valeant Pharmaceuticals Rallies on Morgan Stanley Upgrade

Valeant Pharmaceuticals Rallies on Morgan Stanley Upgrade

Shareholders of the struggling Canadian drugmaker got a major boost in Morgan Stanley's latest analyst note.

Stocks Fluctuate as Fed Minutes Show a Split Central Bank

Stocks Fluctuate as Fed Minutes Show a Split Central Bank

Stocks fluctuate after the release of minutes from the July meeting that showed a Federal Reserve split on its decision over when to raise rates.

Trending Tickers: CIT, VRX, BWLD, BKS

Trending Tickers: CIT, VRX, BWLD, BKS

U.S. markets were down Wednesday as crude oil broke its days-long rally.

Midday Report: Morgan Stanley Backs Valeant; U.S. Stocks Fall

Midday Report: Morgan Stanley Backs Valeant; U.S. Stocks Fall

Stocks fell further from record highs as quarterly disappointments from Target TGT and Lowe's LOW brought down the cyclical consumer sector.